株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

二重特異性抗体医薬品市場:2017-2030年

Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030

発行 ROOTS ANALYSIS 商品コード 283282
出版日 ページ情報 英文 247 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.89円で換算しております。
Back to Top
二重特異性抗体医薬品市場:2017-2030年 Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030
出版日: 2017年09月26日 ページ情報: 英文 247 Pages
概要

当レポートでは、世界の二重特異性抗体医薬品の市場を調査し、抗体・モノクローナル抗体・二重特異性抗体の概要、上市済み製品と臨床パイプラインの状況、上市済み製品およびパイプライン最終段階製品の主要技術・薬剤のプロファイル、上市済み製品およびパイプライン最終段階製品の市場規模の推移と予測、企業間の提携・協力関係の動向、製品のライフサイクル管理戦略および販促/マーケティング戦略のケーススタディなどをまとめています。

第1章 はじめに

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 概要
  • 抗体の概念
  • 抗体の構造
  • 抗体の作用機序
  • モノクローナル抗体
  • 抗体医薬品:有益な市場
  • 抗体ベースの医薬品の進化
  • 二重特異性抗体:形態
    • 一本鎖ベース
    • 免疫グロブリンGベース
  • 二重特異性抗体:作用機序
  • 二重特異性抗体:用途

第4章 市場概要

  • 概要
  • 上市済み製品と臨床パイプライン
  • 製品分布:前臨床段階
  • 製品分布:開発フェーズ別
  • 製品分布:治療区分別
  • 製品分布:作用機序別
  • 製品分布:投薬経路別
  • 製品分布:形態別
  • 製品分布:主要企業別

第5章 技術プラットフォーム

  • 本章の概要
  • 技術プラットフォームリスト
  • 技術プロファイル
    • BiclonicsR:Merus
    • Bispecific T-cell Engager (BiTER):Amgen
    • Dual-Affinity Re-Targeting (DARTR):MacroGenics
    • Modular Antibody Technology?:F-star
    • TandAbR:Affimed
    • ADAPTIR?:Aptevo Therapeutics
    • CrossMAb Technology:Roche
    • DuoBodyR:Genmab
    • NanobodyR:Ablynx
    • XmAb? Antibody Engineering Platform:Xencor

第6章 薬剤プロファイル

  • 本章の概要
  • BLINCYTOR / ブリナツモマブ (Amgen)
  • エミシズマブ / RG6013 (中外製薬 / Roche)
  • ABT-981 (AbbVie)
  • オゾラリズマブ / ATN103 (Ablynx・Eddingpharm・大正製薬)
  • AFM13 (Affimed)
  • Istiratumab / MM-141 (Merrimack Pharmaceuticals)
  • MEDI3902 (MedImmune /AstraZeneca)
  • RG7716 / RO6867461 (Roche / Genentech)
  • SAR156597 (Sanofi)
  • Vobarilizumab, ALX-0061 (Ablynx)

第7章 市場予測・市場機会の分析

  • 本章の概要
  • 範囲・制約
  • 予測手法
  • 総市場
  • 市場予測:薬剤別
    • BLINCYTOR (Amgen)
    • AFM13 (Affimed)
    • Istiratumab (Merrimack Pharmaceuticals)
    • エミシズマブ (中外製薬)
    • ABT-981 (AbbVie)
    • Vobarilizumab (Ablynx)
    • MEDI3902 (AbbVie)
    • RG7716 (Roche)
    • SAR156597 (Sanofi)

第8章 提携・協力

  • 本章の概要
  • 提携モデル
  • 提携リスト
  • 提携分析
    • 提携年別
    • 提携タイプ別
    • 治療エリア別
    • もっとも活発な企業:提携数別

第9章 重要考察

  • 本章の概要
  • パイプライン:ディベロッパー環境
  • パイプライン:治療エリア分析
  • 二重抗体生成プラットフォーム:比較分析
  • レーダーチャート分析

第10章 ケーススタディ:ライフサイクル管理戦略

  • 本章の概要
  • ライフサイクル管理戦略
  • 適応症拡大戦略

第11章 ケーススタディ:販促/マーケティング戦略

  • 本章の概要
  • 販促キャンペーンの各種経路
  • サマリー:製品ウェブサイト分析
  • サマリー:患者サポートサービス・インフォマティブダウンロード
  • サマリー:カンファレンスにおけるプレゼンス
  • BLINCYTOR:販促/マーケティング戦略
  • IclusigR:販促/マーケティング戦略
  • MarqiboR:販促分析

第12章 SWOT分析

第13章 総論

第14章 インタビュー記録

第15章 付録 1:図表データ

第16章 付録 2:企業・組織リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10028

A number of monoclonal antibodies (more than 70) have already been approved for use in humans. These therapeutic products, which target a particular epitope on an antigen, have become a popular and robust treatment option for various diseases. However, despite the success of antibody therapeutics, there are several limitations associated with the use of mono-specific antibodies. It has been reported that certain patients treated using these therapeutic modalities have failed to respond, or have developed resistance to the therapy. Moreover, since the development and progression of several diseases, such as cancer, are dependent on the cross-talk between multiple signaling pathways, molecules directed against a single target may not elicit the desired therapeutic effect.

Bispecific antibodies have demonstrated the capability to address the existing challenges associated with monoclonal antibodies, such as high manufacturing costs, limited applicability in assays and the general lack of understanding of precise in vivo mechanisms of action. Although the concept of bispecific antibodies was conceived more than five decades ago, this field has gained significant popularity in recent years. These molecules have the potential to be used across a broad range of application areas; for example, they can be used to redirect effector cells, simultaneously modulate more than one signaling pathway, and deliver toxic payloads to target sites in a more specific manner. It is also important to highlight that advances in molecular cloning technologies, coupled with a better understanding of antibody engineering techniques, have led to the discovery and development of a number of different bispecific antibody formats, setting them up for use across novel application areas as well.

Synopsis:

The ‘Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030' report provides a comprehensive study of the current landscape of bispecific antibodies, featuring an elaborate discussion on the future potential of this upcoming market. The field has captured the interest of several drug developers, including both small and large companies. As indicated before, the applicability of these engineered biomolecules is vast. Presently, only one bispecific antibody, BLINCYTO® (2014), is available for therapeutic use. However, the development pipeline of bispecific antibody based drugs has several promising candidates that are likely to result in commercial success stories in the foreseen future. The overall pipeline comprises of over 200 molecules that are under development for the treatment of various disease indications across different therapeutic areas, including oncology, autoimmune disorders and infectious diseases. Of these, more than 60 molecules are currently under clinical evaluation, while over 140 product candidates are in the discovery / preclinical stages.

The evolving market has its hopes pinned on multiple start-ups, small and large-sized companies, which are engaged in this domain. Amongst other elements, the report features:

  • A review of the current market landscape, featuring a detailed analysis based on target disease indications / patient segments, phases of development of product candidates (clinical and preclinical / discovery), bispecific antibody formats (fragment based bispecific antibodies, asymmetric bispecific antibodies and symmetric bispecific antibodies), routes of administration (intravenous, subcutaneous, and intravitreal) and mechanisms of action (dual targeting, T-cell engagement, NK-cell engagement, half-life extension and bispecific antibody drug conjugate).
  • Comprehensive profiles of marketed and clinical stage (phase II and above) bispecific antibody therapeutics, highlighting their current status of development, clinical trial information and trial results, and a brief overview, financial performance (if available), and an informed future outlook of the developer.
  • An analysis of the partnerships that have been inked between stakeholders in the industry in the recent past, covering research collaborations, licensing agreements, product development / commercialization agreements, manufacturing agreements, mergers / acquisitions, product development agreements, clinical trial collaboration and other deals.
  • A grid analysis, representing the distribution of the pipeline of bispecific antibodies (on the basis of mechanisms of action of product candidates and antibody formats) across different therapeutic areas and stages of development.
  • A bubble analysis comparing the available technology platforms on the basis of important parameters, such as clinical activity (based on the number of drug candidates developed using a particular technology), number of partnerships established and the size of the developer company.
  • A spider-web analysis highlighting the popularity of different mechanisms of action of bispecific antibody candidates. The analysis takes into consideration various parameters, such as number of bispecific antibodies, number of ongoing clinical trials, target therapeutic indications, number of publications and the companies that are developing these molecules.
  • An elaborate discussion on a lifecycle management strategy, depicting how companies are using indication expansion as a tool to expand their foothold in the field of bispecific antibody therapeutics.
  • A case study on the key promotional strategies adopted for marketing the approved bispecific antibody, BLINCYTO®, and other competitive molecules that have been recently approved for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2017-2030. The research, analysis and insights presented in this report include potential sales of bispecific antibody therapeutics that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel bispecific antibody therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Jane Dancer (CBO, F-star), Ludge Große-Hovest (Founder and CSO, Synimmune), Siobhan Pomeroy (Senior Director, Business Development, CytomX Therapeutics) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. Close to 68% of bispecific antibody based therapeutic products are in the early stages of development (preclinical / discovery), while one bispecific antibody therapeutic (BLINCYTO®) is approved for the treatment of acute lymphoblastic leukemia. 11 products are in advanced clinical evaluation (phase II and above); these include (in alphabetical order) ABT-981 (AbbVie), AFM13 (Affimed), Anti-CD3 MUC1 bispecific antibody (Benhealth Biopharmaceutical), emicizumab (Chugai Pharmaceutical), HER2Bi-Armed Activated T Cells (Barbara Ann Karmanos Cancer Institute), istiratumab (Merrimack Pharmaceuticals), MEDI3902 (MedImmune), ozoralizumab (Ablynx), RG7716 (Roche), SAR156597 (Sanofi) and vobarilizumab (Ablynx).
  • 2. The market landscape is well distributed across small (33), large (30) and mid-sized (25) companies. Some of the prominent small-sized companies engaged in this domain include (in alphabetical order) Affimed, Avillion, Amphivena Therapeutics, Benhealth Biopharmaceutical, EngeneIC and Oxis Biotech. In addition, well established companies, such as (in alphabetical order) Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Emergent BioSolutions, Merck, Pfizer, Roche and Sanofi, are also actively involved in this domain. It is worth mentioning that several universities / research organizations have also contributed to the development of bispecific antibody therapeutics; examples include (in alphabetical order), Barbara Ann Karmanos Cancer Institute, California Institute for Biomedical Research, Duke NeuroSurgery, Fraunhofer Institute of Molecular Biology and Applied Ecology, Sun Yat-Sen University, The First Affiliated Hospital with Nanjing Medical University, The Scripps Research Institute and Vanderbilt Vaccine Center.
  • 3. Bispecific antibodies are capable of simultaneously targeting more than one target and are, therefore, capable of treating clinical conditions that are characterized by cross-talk between multiple disease related pathways. Currently, almost 80% of the development programs are focused on oncological indications, including hematological cancers and solid tumors. Apart from oncology, autoimmune disorders are the most popular; close to 9% of candidate drugs in the pipeline are being developed for such clinical conditions. It is also worth highlighting that the bispecific antibody products are being developed for other therapeutic areas, such as infectious diseases, blood disorders and eye disorders.
  • 4. The market features the presence of a diverse range of bispecific antibody generation platforms, which is indicative of the ongoing innovation in this domain. During our research, we identified around 50 unique platforms that have been developed / are being developed for the generation of different bispecific antibody therapeutics. Of these, we observed that 11 technology platforms are being extensively used; these include (in alphabetical order) Dual Affinity Re-targeting (DART) (MacroGenics), Bispecific T-cell Engager (BiTE) (Amgen), CrossMAb (Roche) and Nanobody (Ablynx)
  • 5. Close to 100 partnerships were inked between various stakeholders in the industry during the period between 2012 and July 2017. Of these, approximately 43% were early R&D related deals; recent examples include Ablynx and Sanofi (July 2017), Numab and Kaken Pharmaceutical (June 2017), and Merus and Institute for Research in Biomedicine, Barcelona (January 2017). Other popular types of collaborations were product / technology licensing agreements (23%), product development and commercialization agreements (16%), manufacturing agreements (4%) and merger / acquisitions (4%). Some of the acquisitions that we came across include Celgene Corporation and EngMab (October 2016), and Aduro Biotech and BioNovion (September 2015).
  • 6. Our future market outlook is highly optimistic as we expect several new drugs to be approved and launched over the coming decade. Examples of drugs in late stages of development include emicizumab, ABT-981, SAR156597, vobarilizumab, istiratumab, AFM13, MEDI3902 and RG7716. In fact, by 2030, we expect the market to grow at an annualized rate of ~34%. Specifically, we believe that emicizumab, istriatumab, ABT-981 and AFM13 will attain blockbuster status and become prime contributors to the market's revenue.
  • 7. Majority of product candidates are T-cell engagers; molecules using this particular mechanism of action are estimated to capture 58% share of the market by 2023. However, in the long term (by 2030), molecules belonging to other product classes having different mechanisms of action, such as blocking cytokines, dual targeting, and half-life extension, are collectively projected to capture almost 75% of the market.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming 10-15 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high level view on the likely evolution of the bispecific antibody therapeutics market in the mid to long term.

Chapter 3 provides a general overview of antibodies covering their historical background, structure, and the types of antibodies available, along with their mechanisms of action. In addition, the chapter highlights the evolution of antibody based therapeutics over the last few years. It also features a discussion on bispecific antibodies, elaborating on the different bispecific formats that are currently available, mechanisms of action of various products / product candidates and their applications.

Chapter 4 includes information on over 200 bispecific antibody therapeutics that are currently in different stages of development. It features a comprehensive analysis of the pipeline molecules, highlighting the target therapeutic areas, phases of development, antibody formats, routes of administration and the corresponding mechanisms of action.

Chapter 5 provides a list of technologies that are either currently available, or being developed by various firms, for the generation of bispecific antibody therapeutics. In addition, it features detailed profiles of some of the key technologies that have been used to develop at least four clinical and / or preclinical bispecific antibody candidates. Each profile contains details on the technology, such as the structure of bispecific antibody, pipeline molecules developed using the technology, its advantages and partnerships established related to the technology.

Chapter 6 contains detailed profiles of drugs that are in advanced stages of clinical development (phase II, filed and marketed). Each profile provides information on the mechanism of action, current status of development, dosage form and treatment regimen, information on clinical studies and key clinical trial results of the drug. It also includes an overview of the developer, its financial details and an informed future outlook.

Chapter 7 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of bispecific antibody therapeutics that are either marketed or are in advanced stages of clinical development (phase II and preregistration). The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key therapeutic areas (oncology, autoimmune disorders, inflammatory disorders, eye disorders and others) and mechanisms of action (T-cell engagement, NK-cell engagement, dual targeting, blocking cytokines and others).

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models and the most common forms of deals / agreements that have been established between 2012 and 2017.

Chapter 9 is a compilation of key insights derived from the study. It presents a detailed logo landscape of the companies engaged in developing bispecific antibody based products, distributed based on the developmental status of pipeline candidates and size of the companies (small, mid-sized and large companies). The chapter also features a grid analysis, representing the distribution of bispecific antibody candidates (on the basis of their mechanisms of action and formats) across target therapeutic areas and stages of development. It also features a comparative study, presented in the form of a bubble analysis, of the different platforms that are being utilized for the generation of bispecific antibodies. The parameters considered for this analysis include the development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and the size of the developer company. Additionally, the chapter features a spider-web analysis, which highlights the activity of bispecific antibodies based on their mechanisms of action. The parameters considered for this analysis include number of drug candidates, active clinical trials, publications, target indications and the companies that are involved in this domain.

Chapter 10 includes a detailed discussion on product life cycle management strategies. It primarily focuses on the indication expansion strategy, which is being used extensively by the developers of bispecific antibody based therapeutics.

Chapter 11 highlights the key promotional strategies that are being implemented by the developer (Amgen) of the marketed bispecific antibody, BLINCYTO® (approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia). For the purpose of this analysis, we also studied the promotional activities of two other drugs, namely Iclusig® and Marqibo®, which are approved for the treatment of the same indication. The promotional aspects covered in the chapter include details provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content, and product visibility in scientific conferences.

Chapter 12 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the bispecific antibodies market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Jane Dancer (CBO, F-star), Ludge Große-Hovest (Founder and CSO, Synimmune), Siobhan Pomeroy (Senior Director, Business Development, CytomX Therapeutics) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. The Concept of Antibody
  • 3.3. The Structure of Antibody
  • 3.4. Mechanism of Action of Antibody
  • 3.5. Monoclonal Antibodies
  • 3.6. Antibody Therapeutics: A Lucrative Market
  • 3.7. Evolution of Antibody Based Therapeutics
    • 3.7.1. Fc Engineering and Glycoengineering of Therapeutic Antibodies
    • 3.7.2. Antibody Fragments
    • 3.7.3. Fusion with Effector Proteins
    • 3.7.4. Intrabodies
    • 3.7.5. Bispecific Antibodies
  • 3.8. Bispecific Antibodies: Formats
    • 3.8.1. Single-Chain-based formats (Fc Independent Antibody Formats)
      • 3.8.1.1. Tandem scFvs and Triplebodies
      • 3.8.1.2. Bispecific Single-Domain Antibody Fusion Proteins
      • 3.8.1.3. Diabodies or Diabody Derivatives
      • 3.8.1.4. Fab Fusion Proteins
      • 3.8.1.5. Other Fc Region-less Fusion Proteins
    • 3.8.2. Immunoglobulin G-Based Formats (Fc Dependent Antibody Formats)
      • 3.8.2.1. Quadromas
      • 3.8.2.2. Knobs-Into-Holes
      • 3.8.2.3. Dual Variable Domain Immunoglobulin (DVD-Ig)
      • 3.8.2.4. IgG-single chain Fv (scFv)
      • 3.8.2.5. Two-in-One or Dual Action Fab (DAF) Antibodies
      • 3.8.2.6. Half Molecule Exchange
      • 3.8.2.7. ιλ- Bodies
  • 3.9. Bispecific Antibodies: Mechanisms of Action
    • 3.9.1. Redirecting Immune Effector Cells towards Tumor Cells
    • 3.9.2. Dual Targeting (Directly Targeting Malignant Cells)
    • 3.9.3. Extending Half-Life
    • 3.9.4. Delivering Cytotoxic Entities to Malignant Cells
    • 3.9.5. Targeting tumor Angiogenesis
    • 3.9.6. Other Mechanisms
  • 3.10. Bispecific Antibodies: Applications

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Bispecific Antibody Therapeutics: Marketed / Clinical Pipeline
  • 4.3. Bispecific Antibody Therapeutics: Preclinical Pipeline
  • 4.4. Bispecific Antibody Therapeutics: Distribution by Phase of Development
  • 4.5. Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
  • 4.6. Bispecific Antibody Therapeutics: Distribution by Mechanism of Action
  • 4.7. Bispecific Antibody Therapeutics: Distribution by Route of Administration
  • 4.8. Bispecific Antibody Therapeutics: Distribution by Type of Format
  • 4.9. Bispecific Antibody Therapeutics: Distribution by Key Players

5. BISPECIFIC ANTIBODY THERAPEUTICS: TECHNOLOGY PLATFORMS

  • 5.1. Chapter Overview
  • 5.2. Bispecific Antibody Therapeutics: List of Technology Platforms
  • 5.3. Bispecific Antibody Therapeutics: Technology Profiles
    • 5.3.1. Biclonics®, Merus
      • 5.3.1.1. Overview
      • 5.3.1.2. Technology Details
      • 5.3.1.3. Structure of Biclonics® Bispecific Antibodies
      • 5.3.1.4. Pipeline of Biclonics® Bispecific Antibodies
      • 5.3.1.5. Advantages of Biclonics® Bispecific Antibodies
      • 5.3.1.6. Collaborations and Partnerships
    • 5.3.2. Bispecific T-cell Engager (BiTE®), Amgen
      • 5.3.2.1. Overview
      • 5.3.2.2. Technology Details
      • 5.3.2.3. Structure of BiTE® Bispecific Antibodies
      • 5.3.2.4. Pipeline of BiTE® Bispecific Antibodies
      • 5.3.2.5. Advantages of BiTE® Bispecific Antibodies
      • 5.3.2.6. Collaborations and Partnerships
    • 5.3.3. Dual-Affinity Re-Targeting (DART®), MacroGenics
      • 5.3.3.1. Overview
      • 5.3.3.2. Technology Details
      • 5.3.3.3. Structure of DART® Bispecific Antibodies
      • 5.3.3.4. Pipeline of DART® Bispecific Antibodies
      • 5.3.3.5. Advantages of DART® Bispecific Antibodies
      • 5.3.3.6. Collaborations and Partnerships
    • 5.3.4. Modular Antibody Technology™, F-star
      • 5.3.4.1. Overview
      • 5.3.4.2. Technology Details
      • 5.3.4.3. Structure of Modular Antibody Technology™ based Bispecific Antibodies
      • 5.3.4.4. Pipeline of Modular Antibody Technology™ based Bispecific Antibodies
      • 5.3.4.5. Advantages of Modular Antibody Technology™ based Bispecific Antibodies
      • 5.3.4.6. Collaborations and Partnerships
    • 5.3.5. TandAb®, Affimed
      • 5.3.5.1. Overview
      • 5.3.5.2. Technology Details
      • 5.3.5.3. Structure of TandAb® Bispecific Antibodies
      • 5.3.5.4. Pipeline of TandAb® Bispecific Antibodies
      • 5.3.5.5. Advantages of TandAb® Bispecific Antibodies
      • 5.3.5.6. Collaborations and Partnerships
    • 5.3.6. ADAPTIR™, Aptevo Therapeutics
    • 5.3.7. CrossMAb Technology, Roche
    • 5.3.8. DuoBody®, Genmab
    • 5.3.9. Nanobody®, Ablynx
    • 5.3.10. XmAb™ Antibody Engineering Platform, Xencor

6. DRUG PROFILES

  • 6.1. Chapter Overview
  • 6.2. BLINCYTO® / Blinatumomab (Amgen)
    • 6.2.1. Overview
    • 6.2.2. Mechanism of Action
    • 6.2.3. Current Status of Development
    • 6.2.4. Clinical Trials
    • 6.2.5. Clinical Findings
    • 6.2.6. Annual Sales
    • 6.2.7. Amgen
      • 6.2.7.1. Overview
      • 6.2.7.2. Financial Information
      • 6.2.7.3. Future Outlook
  • 6.3. Emicizumab / RG6013 (Chugai Pharmaceutical / Roche)
    • 6.3.1. Overview
    • 6.3.2. Mechanism of Action
    • 6.3.3. Current Status of Development
    • 6.3.4. Clinical Trials
    • 6.3.5. Clinical Findings
    • 6.3.6. Chugai Pharmaceutical
      • 6.3.6.1. Overview
      • 6.3.6.2. Financial Information
      • 6.3.6.3. Future Outlook
  • 6.4. ABT-981 (AbbVie)
    • 6.4.1. Overview
    • 6.4.2. Mechanism of Action
    • 6.4.3. Current Status of Development
    • 6.4.4. Clinical Trials
    • 6.4.5. Clinical Findings
    • 6.4.6. AbbVie
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Information
      • 6.4.6.3. Future Outlook
  • 6.5. Ozoralizumab / ATN103 (Ablynx, Eddingpharm, Taisho Pharmaceutical)
    • 6.5.1. Overview
    • 6.5.2. Mechanism of Action
    • 6.5.3. Current Status of Development
    • 6.5.4. Clinical Trials
    • 6.5.5. Clinical Findings
    • 6.5.6. Ablynx
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Information
      • 6.5.6.3. Future Outlook
  • 6.6. AFM13 (Affimed)
    • 6.6.1. Overview
    • 6.6.2. Mechanism of Action
    • 6.6.3. Current Status of Development
    • 6.6.4. Clinical Trials
    • 6.6.5. Clinical Findings
    • 6.6.6. Affimed
      • 6.6.6.1. Overview
      • 6.6.6.2. Financial Information
      • 6.6.6.3. Future Outlook
  • 6.7. Istiratumab / MM-141 (Merrimack Pharmaceuticals)
    • 6.7.1. Overview
    • 6.7.2. Mechanism of Action
    • 6.7.3. Current Status of Development
    • 6.7.4. Clinical Trials
    • 6.7.5. Clinical Findings
    • 6.7.6. Merrimack Pharmaceuticals
      • 6.7.6.1. Overview
      • 6.7.6.2. Financial Information
      • 6.7.6.3. Future Outlook
  • 6.8. MEDI3902 (MedImmune /AstraZeneca)
    • 6.8.1. Overview
    • 6.8.2. Mechanism of Action
    • 6.8.3. Current Status of Development
    • 6.8.4. Clinical Trials
    • 6.8.5. AstraZeneca
      • 6.8.5.1. Overview
      • 6.8.5.2. Financial Information
      • 6.8.5.3. Future Outlook
  • 6.9. RG7716 / RO6867461 (Roche / Genentech)
    • 6.9.1. Overview
    • 6.9.2. Mechanism of Action
    • 6.9.3. Current Status of Development
    • 6.9.4. Clinical Trials
    • 6.9.5. Clinical Findings
    • 6.9.6. Roche
      • 6.9.6.1. Overview
      • 6.9.6.2. Financial Information
      • 6.9.6.3. Future Outlook
  • 6.10. SAR156597 (Sanofi)
    • 6.10.1. Overview
    • 6.10.2. Mechanism of Action
    • 6.10.3. Current Status of Development
    • 6.10.4. Clinical Trials
    • 6.10.5. Sanofi
      • 6.10.5.1. Overview
      • 6.10.5.2. Financial Information
      • 6.10.5.3. Future Outlook
  • 6.11. Vobarilizumab, ALX-0061 (Ablynx)
    • 6.11.1. Overview
    • 6.11.2. Mechanism of Action
    • 6.11.3. Current Status of Development
    • 6.11.4. Clinical Trials
    • 6.11.5. Clinical Findings
    • 6.11.6. Ablynx
      • 6.11.6.1. Overview
      • 6.11.6.2. Financial Information
      • 6.11.6.3. Future Outlook

7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Limitations
  • 7.3. Forecast Methodology
  • 7.4. Overall Bispecific Antibody Therapeutics Market
  • 7.5. Bispecific Antibody Therapeutics Market: Individual Drug Forecasts
    • 7.5.1. BLINCYTO® (Amgen)
      • 7.5.1.1. Target Patient Population
      • 7.5.1.2. Sales Forecast
    • 7.5.2. AFM13 (Affimed)
      • 7.5.2.1. Target Patient Population
      • 7.5.2.2. Sales Forecast
    • 7.5.3. Istiratumab (Merrimack Pharmaceuticals)
      • 7.5.3.1. Target Patient Population
      • 7.5.3.2. Sales Forecast
    • 7.5.4. Emicizumab (Chugai Pharmaceutical)
      • 7.5.4.1. Target Patient Population
      • 7.5.4.2. Sales Forecast
    • 7.5.5. ABT-981 (AbbVie)
      • 7.5.5.1. Target Patient Population
      • 7.5.5.2. Sales Forecast
    • 7.5.6. Vobarilizumab (Ablynx)
      • 7.5.6.1. Target Patient Population
      • 7.5.6.2. Sales Forecast
    • 7.5.7. MEDI3902 (AbbVie)
      • 7.5.7.1. Target Patient Population
      • 7.5.7.2. Sales Forecast
    • 7.5.8. RG7716 (Roche)
      • 7.5.8.1. Target Patient Population
      • 7.5.8.2. Sales Forecast
    • 7.5.9. SAR156597 (Sanofi)
      • 7.5.9.1. Target Patient Population
      • 7.5.9.2. Sales Forecast

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Bispecific Antibody Therapeutics: List of Partnerships
  • 8.4. Bispecific Antibody Therapeutics: Partnership Analysis
    • 8.4.1. Analysis by Year of Partnerships
    • 8.4.2. Analysis by Type of Partnership
    • 8.4.3. Analysis by Type of Therapeutic Area
    • 8.4.4. Most Active Companies: Analysis by Number of Partnership

9. KEY INSIGHTS

  • 9.1. Chapter Overview
  • 9.2. Bispecific Antibodies Pipeline: Developer Landscape
  • 9.3. Bispecific Antibodies Pipeline: Therapeutic Area Analysis
  • 9.4. Bispecific Antibody Generation Platforms: Comparative Analysis
  • 9.5. Bispecific Antibody Therapeutics: Spider-Web Analysis

10. CASE STUDY: LIFE CYCLE MANAGEMENT STRATEGIES

  • 10.1. Chapter Overview
  • 10.2. Life Cycle Management Strategies
  • 10.3. Indication Expansion Strategy

11. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES

  • 11.1. Chapter Overview
  • 11.2. Different Channels of Promotional Campaigns
  • 11.3. Summary: Product Website Analysis
  • 11.4. Summary: Patient Support Services and Informative Downloads
  • 11.5. Summary: Presence in conferences
  • 11.6. BLINCYTO®: Promotional / Marketing Strategy
    • 11.6.1. Drug Overview
    • 11.6.2. Product Website Analysis
      • 11.6.2.1. Messages for Healthcare Professionals
    • 11.6.3. Patient Support Services and Informative Downloads
    • 11.6.4. Presence in Conferences
  • 11.7. Iclusig®: Promotional / Marketing Strategy
    • 11.7.1. Drug Overview
    • 11.7.2. Product Website Analysis
      • 11.7.2.1. Messages for Patients
      • 11.7.2.2. Messages for Healthcare Professionals
    • 11.7.3. Patient Support Services and Informative Downloads
    • 11.7.4. Presence in Conferences
  • 11.8. Marqibo®: Promotional Analysis
    • 11.8.1. Drug Overview
    • 11.8.2. Product Website analysis
      • 11.8.2.1. Messages for Patients
      • 11.8.2.2. Messages for Healthcare Professionals
    • 11.8.3. Patient Support Services and Informative Downloads
    • 11.8.4. Presence in Conferences

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weakness
  • 12.4. Opportunities
  • 12.5. Threats

13. CONCLUSION

  • 13.1. With Multiple Late-phase Candidates, The Bispecific Antibody Therapeutics Market is Characterized by a Robust and Promising Pipeline
  • 13.2. Product Candidates are Being Developed to Treat a Number of Clinical Conditions, With the Primary Focus Being on Oncology
  • 13.3. The Current Market Features an Even Mix of Small-sized, Mid-sized and Large-sized Companies
  • 13.4. Extensive R&D Efforts in this Domain have Led to the Development of Innovative Platform Technologies
  • 13.5. Several Stakeholders have Entered into Strategic Alliances to Further R&D and Product Development Efforts
  • 13.6. Post the Approval and Launch of Multiple Late-Phase Product Candidates, the Market is Expected to Grow at a Rapid Pace
  • 13.7. Concluding Remarks

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. Siobhan Pomeroy, Senior Director, Business Development, CytomX Therapeutics
  • 14.3. Jane Dancer, Chief Business Officer O, F-star
  • 14.4. Yinjue Wang, Associate Director, Process development, Innovent Biologics
  • 14.5. Ludger Große-Hovest, Chief Scientific Officer, Synimmune

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1: Antibody: Key Historic Events
  • Figure 3.2: Basic Structure of an Antibody
  • Figure 3.3: Mechanisms of Action of Antibodies
  • Figure 3.4: Revenues of the Top 15 Drugs, 2016(USD Billion)
  • Figure 3.5: Structure: Symmetric and Asymmetric Bispecific Antibodies
  • Figure 4.1: Bispecific Antibody Therapeutics: Distribution by Phase of Development
  • Figure 4.2: Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
  • Figure 4.3: Bispecific Antibody Therapeutics: Distribution by Mechanism of Action
  • Figure 4.4: Bispecific Antibody Therapeutics: Distribution by Route of Administration
  • Figure 4.5: Bispecific Antibody Therapeutics: Distribution by Type of Format
  • Figure 4.6: Bispecific Antibody Therapeutics: Distribution by Key Players
  • Figure 5.1: Biclonics® Bispecific Antibody: Structure
  • Figure 5.2: BiTE® Bispecific Antibody: Structure
  • Figure 5.3: DART® Bispecific Antibody: Structure
  • Figure 5.4: Modular Antibody Technology™ Bispecific Antibody: Structure
  • Figure 5.5: TandAb® Bispecific Antibody: Structure
  • Figure 5.6: ADAPTIR™ Bispecific Antibody: Structure
  • Figure 5.7: CrossMAb Bispecific Antibody: Structure
  • Figure 5.8: DuoBody® Bispecific Antibody: Structure
  • Figure 5.9: Nanobody® Bispecific Antibody: Structure
  • Figure 6.1: BLINCYTO®: Annual Sales, 2015-H1 2017(USD Million)
  • Figure 6.2: Amgen: Annual Revenues, 2012-H1 2017(USD Billion)
  • Figure 6.3: Chugai Pharmaceutical: Annual Revenues, 2012-Q1 2017(JPY Billion)
  • Figure 6.4: AbbVie: Annual Revenues, 2012-H1 2017(USD Billion)
  • Figure 6.5: Ablynx: Annual Revenues, 2012-H1 2017(EUR Million)
  • Figure 6.6: Affimed: Annual Revenues, 2012- H1 2017(EUR Million)
  • Figure 6.7: Merrimack Pharmaceuticals: Annual Revenues, 2012-H1 2017(USD Million)
  • Figure 6.8: AstraZeneca: Annual Revenues, 2012-H1 2017(USD Billion)
  • Figure 6.9: Roche: Annual Revenues, 2012-H1 2017(CHF Billion)
  • Figure 6.10: Sanofi: Annual Revenues, 2012-H1 2017(EUR Billion)
  • Figure 7.1: Overall Bispecific Antibody Therapeutics Market, 2017-2030: Base Scenario(USD Billion)
  • Figure 7.2: Bispecific Antibody Therapeutics Market(USD Billion), 2017, 2023 and 2030(Base Scenario): Distribution by Therapeutic Area
  • Figure 7.3: Bispecific Antibody Therapeutics Market(USD Billion), 2017, 2023 and 2030(Base Scenario): Distribution by Mechanism of Action
  • Figure 7.4: Bispecific Antibody Therapeutics Market(USD Billion), 2017, 2023 and 2030(Base Scenario): Distribution by Drugs
  • Figure 7.5: BLINCYTO® Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.6: AFM13 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.7: Istiratumab Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.8: Emicizumab Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.9: ABT-981 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.10: Vobarilizumab Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.11: MEDI3902 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.12: RG7716 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 7.13: SAR156597 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Figure 8.1: Bispecific Antibody Therapeutics Partnerships: Cumulative Trend by Year(2012-2017)
  • Figure 8.2: Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Partnership
  • Figure 8.3: Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Therapeutic Area
  • Figure 8.4: Bispecific Antibody Therapeutics Partnerships: Most Active Companies
  • Figure 9.1: Bispecific Antibody Therapeutics Market: Developer Landscape
  • Figure 9.2: Bispecific Antibody Therapeutics Clinical Pipeline: Therapeutic Area Analysis
  • Figure 9.3: Bispecific Antibody Therapeutics Early Stage Pipeline: Therapeutic Area Analysis
  • Figure 9.4: Bispecific Antibodies Generation Platforms: 3-Dimensional Comparative Analysis
  • Figure 9.5: Bispecific Antibody Mechanisms of Action: 5-Dimensional Spider-Web Analysis
  • Figure 10.1: Bispecific Antibody Therapeutics: LCM Strategy Heat Map Analysis
  • Figure 10.2: Bispecific Antibody Therapeutics: LCM Strategy(Indication Expansion)
  • Figure 11.1: Promotional / Marketing Strategy: Product Website Analysis
  • Figure 11.2: Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
  • Figure 11.3: Promotional / Marketing Strategy: Presence in Conferences
  • Figure 11.4: BLINCYTO®: Product Website Analysis(Messages for Healthcare Professionals)
  • Figure 11.5: BLINCYTO®: Amgen Assist 360 Nurse Ambassador
  • Figure 11.6: BLINCYTO®: Presence in Conferences
  • Figure 11.7: Iclusig®: Product Website Analysis(Messages for Patients)
  • Figure 11.8: Iclusig®: Product Website Analysis(Messages for Healthcare Professionals)
  • Figure 11.9: Iclusig®: Point Program
  • Figure 11.10: Iclusig®: Presence in Conferences
  • Figure 11.11: Marqibo®: Product Website Analysis(Messages for Patients)
  • Figure 11.12: Marqibo®: Product Website Analysis(Messages for Healthcare Professionals)
  • Figure 11.13: Marqibo®: STAR Program
  • Figure 11.14: Marqibo®: Presence in Conferences
  • Figure 13.1: Bispecific Antibody Therapeutics Market, 2017, 2023, and 2030: Conservative, Base and Optimistic Scenarios(USD Billion)

List of Tables

  • Table 3.1: Mechanisms of Action of Therapeutic Antibodies Against Different Target Classes
  • Table 3.2: Top Ten Therapeutic Antibodies 2016
  • Table 4.1: Bispecific Antibody Therapeutics: Marketed / Clinical Pipeline
  • Table 4.2: Bispecific Antibody Therapeutics: Preclinical Pipeline
  • Table 5.1: Bispecific Antibody Therapeutics: List of Technology Platforms
  • Table 5.2: Biclonics® Bispecific Antibodies: Development Pipeline
  • Table 5.3: BiTE® Bispecific Antibodies: Development Pipeline
  • Table 5.4: DART® Bispecific Antibodies: Development Pipeline
  • Table 5.5: Modular Antibody Technology™ based Bispecific Antibodies: Development Pipeline
  • Table 5.6: TandAb® Bispecific Antibodies: Development Pipeline
  • Table 5.7: ADAPTIR™ Bispecific Antibodies: Development Pipeline
  • Table 5.8: CrossMAb Bispecific Antibodies: Development Pipeline
  • Table 5.9: DuoBody® Bispecific Antibodies: Development Pipeline
  • Table 5.10: Nanobody® Bispecific Antibodies: Development Pipeline
  • Table 5.11: XmAb™ Bispecific Antibodies: Development Pipeline
  • Table 6.1: Bispecific Antibody Therapeutics: Approved / Late-Stage Molecules
  • Table 6.2: BLINCYTO®: Current Status of Development
  • Table 6.3: BLINCYTO®: Clinical Trials
  • Table 6.4: BLINCYTO®: Results of the(TOWER Study)
  • Table 6.5: BLINCYTO®: Efficacy Results(ALCANTARA Study)
  • Table 6.6: Amgen: Bispecific Antibody Product Portfolio
  • Table 6.7: Emicizumab: Current Status of Development
  • Table 6.8: Emicizumab: Clinical Trials
  • Table 6.9: Emicizumab: Design of Phase I Trial(ACE001JP)
  • Table 6.10: Emicizumab: Mean Annualized Bleeding Rate in Phase I Trial(ACE001JP)
  • Table 6.11: Emicizumab Phase I/II: Mean Annualized Bleeding Rate / Annualized Joint Bleeding Rate in Phase I/II Trial
  • Table 6.12: ABT-981: Current Status of Development
  • Table 6.13: ABT-981: Clinical Trials
  • Table 6.14: AbbVie: Bispecific Antibody Product Portfolio
  • Table 6.15: Ozoralizumab: Current Status of Development
  • Table 6.16: Ozoralizumab: Clinical Trials
  • Table 6.17: Ozoralizumab: ACR20, ACR50 and ACR70 in Phase II Trial(NCT01063803)
  • Table 6.18: Ozoralizumab: Safety Results of Phase II Trial(NCT01063803)
  • Table 6.19: Ablynx: Bispecific Antibody Product Portfolio
  • Table 6.20: AFM13: Current Status of Development
  • Table 6.21: AFM13: Clinical Trials
  • Table 6.22: Affimed: Bispecific Antibody Product Portfolio
  • Table 6.23: MM-141: Current Status of Development
  • Table 6.24: MM-141: Clinical Trials
  • Table 6.25: MEDI3902: Current Status of Development
  • Table 6.26: MEDI3902: Clinical Trials
  • Table 6.27: RG7716: Current Status of Development
  • Table 6.28: RG-7716: Clinical Trials
  • Table 6.29: Roche: Bispecific Antibody Product Portfolio
  • Table 6.30: SAR156597: Current Status of Development
  • Table 6.31: SAR156597: Clinical Trials
  • Table 6.32: Vobarilizumab: Current Status of Development
  • Table 6.33: Vobarilizumab: Clinical Trials
  • Table 6.34: Vobarilizumab Monotherapy: Results of the Phase II Study
  • Table 6.35: Vobarilizumab Monotherapy: Safety Results
  • Table 7.1: Bispecific Antibody Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
  • Table 7.2: BLINCYTO®: Target Patient Population
  • Table 7.3: AFM13: Target Patient Population
  • Table 7.4: Istiratumab: Target Patient Population
  • Table 7.5: Emicizumab: Target Patient Population
  • Table 7.6: ABT-981: Target Patient Population
  • Table 7.7: Vobarilizumab: Target Patient Population
  • Table 7.8: MEDI3902: Target Patient Population
  • Table 7.9: RG7716: Target Patient Population
  • Table 7.10: SAR156597: Target Patient Population
  • Table 8.1: Bispecific Antibody Therapeutics: Recent Partnerships
  • Table 9.1: Bispecific Antibody Therapeutics: Spider-Web Analysis
  • Table 11.1: BLINCYTO®: Drug Overview
  • Table 11.2: Iclusig®: Drug Overview
  • Table 11.3: Marqibo®: Drug Overview
  • Table 12.1: Bispecific Antibody Therapeutics: SWOT Analysis
  • Table 12.2: Bispecific Antibody Therapeutics: Contract Manufacturing Organizations
  • Table 15.1: Revenues of the Top 15 Drugs, 2016(USD Billion)
  • Table 15.2: Bispecific Antibody Therapeutics: Distribution by Phase of Development
  • Table 15.3: Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
  • Table 15.4: Bispecific Antibody Therapeutics: Distribution by Mechanism of Action
  • Table 15.5: Bispecific Antibody Therapeutics: Distribution by Route of Administration
  • Table 15.6: Bispecific Antibody Therapeutics: Distribution by Type of Format
  • Table 15.7: Bispecific Antibody Therapeutics: Distribution by Key Players
  • Table 15.8: BLINCYTO®: Annual Sales, 2015-H1 2017(USD Million)
  • Table 15.9: Amgen: Annual Revenues, 2012-H1 2017(USD Billion)
  • Table 15.10: Chugai Pharmaceutical: Annual Revenues, 2012-H1 2017(JPY Billion)
  • Table 15.11: AbbVie: Annual Revenues, 2012-H1 2017(USD Billion)
  • Table 15.12: Ablynx: Annual Revenues, 2012-H1 2017(EUR Million)
  • Table 15.13: Affimed Therapeutics: Annual Revenues, 2012- H1 2017(EUR Million)
  • Table 15.14: Merrimack Pharmaceuticals: Annual Revenues, 2012-H1 2017(USD Million)
  • Table 15.15: AstraZeneca: Annual Revenues, 2012-H1 2017(USD Billion)
  • Table 15.16: Roche: Annual Revenues, 2012-H1 2017(CHF Billion)
  • Table 15.17: Sanofi: Annual Revenues, 2012-H1 2017(EUR Billion)
  • Table 15.18: Overall Bispecific Antibody Therapeutics Market, 2017-2030: Base Scenario(USD Billion)
  • Table 15.19: Overall Bispecific Antibody Therapeutics Market, 2017-2030: Optimistic Scenario(USD Billion)
  • Table 15.20: Overall Bispecific Antibody Therapeutics Market, 2017-2030: Conservative Scenario(USD Billion)
  • Table 15.21: Bispecific Antibody Therapeutics Market(USD Million), 2017, 2023 and 2030(Base Scenario): Distribution by Therapeutic Area
  • Table 15.22: Bispecific Antibody Therapeutics Market(USD Million), 2017, 2023 and 2030(Base Scenario): Distribution by Mechanism of Action
  • Table 15.23: Bispecific Antibody Therapeutics Market(USD Million), 2017, 2023 and 2030(Base Scenario): Distribution by Drugs
  • Table 15.24: BLINCYTO® Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.25: BLINCYTO® Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.26: BLINCYTO® Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.27: AFM13 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.28: AFM13 Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.29: AFM13 Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.30: Istiratumab Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.31: Istiratumab Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.32: Istiratumab Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.33: Emicizumab Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.34: Emicizumab Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.35: Emicizumab Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.36: ABT-981 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.37: ABT-981 Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.38: ABT-981 Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.39: Vobarilizumab Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.40: Vobarilizumab Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.41: Vobarilizumab Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.42: MEDI3902 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.43: MEDI3902 Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.44: MEDI3902 Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.45: RG7716 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.46: RG7716 Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.47: RG7716 Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.48: SAR156597 Sales Forecast(Till 2030): Base Scenario(USD Million)
  • Table 15.49: SAR156597 Sales Forecast(Till 2030): Optimistic Scenario(USD Million)
  • Table 15.50: SAR156597 Sales Forecast(Till 2030): Conservative Scenario(USD Million)
  • Table 15.51: Bispecific Antibody Therapeutics Partnerships: Cumulative Trend by Year(2012-2017)
  • Table 15.52: Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Partnership
  • Table 15.53: Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Therapeutic Area
  • Table 15.54: Bispecific Antibody Therapeutics Partnerships: Most Active Companies
  • Table 15.55: Summary: Presence in Conferences
  • Table 15.56: Bispecific Antibody Therapeutics Market(USD Billion), 2017, 2023 and 2030

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. Abbott
  • 2. AbbVie
  • 3. AbCheck
  • 4. AbClon
  • 5. Ablynx
  • 6. AbMed (a subsidiary of Abpro)
  • 7. Abpro
  • 8. Abzena
  • 9. Adimab
  • 10. Aduro Biotech
  • 11. Advagene Biopharma
  • 12. Advaxis Immunotherapies
  • 13. Affimed
  • 14. Agenus
  • 15. Ajou University, South Korea
  • 16. Albert Einstein College of Medicine, US
  • 17. Alexo Therapeutics
  • 18. Alissa Pharma
  • 19. Alligator Bioscience
  • 20. Alnylam Pharmaceuticals
  • 21. Ambrx
  • 22. Amgen
  • 23. Amphivena Therapeutics
  • 24. AnaptysBio
  • 25. AP Biosciences
  • 26. Aptevo Therapeutics
  • 27. ARIAD Pharmaceuticals
  • 28. Arrowhead Pharmaceuticals
  • 29. AstraZeneca
  • 30. Atlante Biotech
  • 31. Avillion
  • 32. Balgrist University Hospital, Switzerland
  • 33. Baliopharm (acquired by Alvotech)
  • 34. Barbara Ann Karmanos Cancer Institute, US
  • 35. Baxalta
  • 36. Bayer
  • 37. Benhealth Biopharmaceutical
  • 38. Beth Israel Deaconess Medical Center, US
  • 39. BIOCAD
  • 40. Biocells (Beijing) Biotech
  • 41. Biogen
  • 42. BioInvent International
  • 43. BioLineRx
  • 44. BIOMUNEX Pharmaceuticals
  • 45. BioNovion (acquired by Aduro Biotech)
  • 46. BioNTech
  • 47. Biotecnol
  • 48. Bioverativ
  • 49. Boehringer Ingelheim
  • 50. California Institute for Biomedical Research, US
  • 51. Catalent Biologics
  • 52. Celgene
  • 53. Cepheid
  • 54. ChemPartner
  • 55. Chugai Pharmaceutical
  • 56. CMC Biologics
  • 57. Columbia University, US
  • 58. Cormorant Pharmaceuticals (acquired by Bristol-Myers Squibb)
  • 59. Covagen (acquired by Cilag)
  • 60. Creative Biolabs
  • 61. CytomX Therapeutics
  • 62. Daiichi Sankyo
  • 63. Denali Therapeutics
  • 64. Duke Neurosurgery, US
  • 65. Dutalys
  • 66. Eddingpharm
  • 67. Eli Lilly
  • 68. Emergent BioSolutions
  • 69. EnGeneIC
  • 70. EngMab (acquired by Celgene)
  • 71. EpimAb Biotherapeutics
  • 72. Fabion Pharmaceuticals
  • 73. Fidelity Management & Research
  • 74. Five Prime Therapeutics
  • 75. Flatiron Health
  • 76. Foundation Medicine
  • 77. Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Germany
  • 78. Fresenius Biotech
  • 79. F-star
  • 80. Fudan University, China
  • 81. Fusion Antibodies
  • 82. FZata
  • 83. Ganymed Pharmaceuticals (acquired by Astellas Pharma)
  • 84. Genentech
  • 85. General Electric (GE)
  • 86. Genmab
  • 87. Genzyme
  • 88. German Cancer Research Center (DKFZ), Germany
  • 89. Gilead Sciences
  • 90. Glaxo Smith Kline (GSK)
  • 91. Glenmark Pharmaceuticals
  • 92. Goodwin Biotechnology
  • 93. Guangdong Medical University, China
  • 94. Gustave Roussy
  • 95. Hanmi Pharmaceutical
  • 96. Hanwha Chemical R&D Center, Korea
  • 97. Harvard University, US
  • 98. Henlix Biotech
  • 99. Humabs BioMed
  • 100. Human Longevity
  • 101. i2 Pharmaceuticals
  • 102. IGM Biosciences
  • 103. Immatics Biotechnologies
  • 104. Immune Pharmaceuticals
  • 105. Immunomedics
  • 106. Imunexus
  • 107. Incyte
  • 108. InflaRx
  • 109. Innate Pharma
  • 110. Innovent Biologics
  • 111. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland
  • 112. Institute for Research in Biomedicine (IRB) Barcelona, Spain
  • 113. Intarcia Therapeutics
  • 114. Ipsen
  • 115. Janssen Biotech
  • 116. Janssen-Cilag
  • 117. JW Pharmaceutical
  • 118. Kairos Therapeutics
  • 119. Kymab
  • 120. Kyowa Hakko Kirin
  • 121. Leica Biosystems
  • 122. Leland Stanford Junior University, US
  • 123. Leukemia and Lymphoma Society, US
  • 124. Ligand Pharmaceuticals
  • 125. LINDIS Biotech
  • 126. MacroGenics
  • 127. Masonic Cancer Center, US
  • 128. Massachusetts General Hospital, US
  • 129. Massachusetts Institute of Technology (MIT), US
  • 130. MediaPharma
  • 131. MedImmune
  • 132. Memorial Sloan Kettering Cancer Center, US
  • 133. Merck
  • 134. Merrimack Pharmaceuticals
  • 135. Merus
  • 136. Micromet
  • 137. Mitsubishi Tanabe Pharma
  • 138. MorphoSys
  • 139. Nanjing Abingen
  • 140. Nanjing Medical University, China
  • 141. National Cancer Institute (NCI), US
  • 142. Neovii Biotech
  • 143. Northeast Agricultural University, China
  • 144. Novartis
  • 145. Novimmune
  • 146. Novo Nordisk
  • 147. Numab
  • 148. OcellO
  • 149. OncoMed Pharmaceuticals
  • 150. Ono Pharmaceutical
  • 151. Oxis Biotech
  • 152. Pfizer
  • 153. PharmAbcine
  • 154. Pharmacyclics
  • 155. Pieris Pharmaceuticals
  • 156. Regeneron Pharmaceuticals
  • 157. RenMin Hospital, Wuhan University, China
  • 158. Roche
  • 159. Samsung Advanced Institute of Technology (SAIT), South Korea
  • 160. Sanofi
  • 161. SATT Sud-Est
  • 162. SBI Pharmaceuticals
  • 163. Sea Lane Biotechnologies
  • 164. Second Military Medical University, Shanghai
  • 165. Selexis
  • 166. Servier
  • 167. Shire
  • 168. SiteOne Therapeutics
  • 169. Spectrum Pharmaceuticals
  • 170. Stanford University, US
  • 171. Stemcentrx
  • 172. Sun Yat-sen University, China
  • 173. Sutro Biopharma
  • 174. Synergys
  • 175. Synimmune
  • 176. Systimmune
  • 177. Taisho Pharmaceutical
  • 178. Takeda Pharmaceutical
  • 179. Teijin Pharma
  • 180. TESARO
  • 181. The Scripps Research Institute, US
  • 182. The University of Texas MD Anderson Cancer Center, US
  • 183. Tianjin Nankai Hospital, China
  • 184. TriOn Pharma
  • 185. University of California, Los Angeles (UCLA), US
  • 186. University of Cologne, Germany
  • 187. University of Groningen, Netherlands
  • 188. University of Minnesota, US
  • 189. University of Munich, Germany
  • 190. University of Virginia, US
  • 191. Van Herk Investments
  • 192. Vanderbilt Vaccine Center, US
  • 193. Vrije Universiteit Brussel, Belgium
  • 194. Wal-Mart
  • 195. Warburg Pincus
  • 196. Wellcome Trust Sanger Institute, England
  • 197. Wuhan YZY Biopharma
  • 198. WuXi Biologics
  • 199. Xencor
  • 200. Y-mAbs Therapeutics
  • 201. Zhejiang Hisun Pharmaceutical
  • 202. Zymeworks
  • 203. Zyngenia
Back to Top